糖胰生2号对糖耐量减低的临床干预及对糖尿病大鼠血清GLP-1的影响

发布时间：2018-06-30 09:47

本文选题：糖耐量减低 + 糖胰生2号　；参考：《山东中医药大学》2016年硕士论文

【摘要】：目的:通过临床观察及动物实验研究两个方面探讨糖胰生2号方对糖耐量减低常患者的疗效以及对糖尿病大鼠血清胰岛素以及胰高血糖素样肽1的影响。方法:1.临床研究:将60例糖耐量减低患者随机分为治疗组和对照组,每组各30例,治疗组:给予糖胰生2号联合合理饮食及运动。对照组:合理饮食及运动。观察两组患者治疗前后症状、血糖血脂、体重指数、胰岛素抵抗指数等的变化情况。2.实验研究:采用二联造模方法(高糖高脂饲料+适量STZ腹腔注射)建立糖尿病大鼠模型,药物干预6周后,采用酶联免疫检测方法观察大鼠的血清胰岛素以及胰高血糖素样肽1的水平。结果:临床结果:治疗组中医症状体征有所改善(P0.05),和对照组相比具有明显的优势(P0.01);治疗组FPG、2h PG及Hb A1c、TC、TG、LDL-C水平均显著降低,组间比较有差异性(P0.05),HDL-C有所上升但组间无显著差异;与对照组相比,治疗组显著降低BMI指数(P0.05)。实验结果:与模型组相比较,中药组以及二甲双胍、西格列汀组均能降低体重及空腹血糖(P0.05),中药高剂量组具有显著优势(P0.01);西格列汀及中药组分别与模型组相比较,在升高空腹胰岛素方面具有明显的优势(P0.01),且中药组比二甲双胍及西格列汀组更为有效(P0.05);与模型组相比,二甲双胍、西格列汀组及中药组胰岛素抵抗指数显著降低(P0.01),但中药组与二甲双胍组及西格列汀组相比无统计学意义(P0.05);与模型组相比二甲双胍组及西格列汀组大鼠血清GLP-1水平有所上升,但是无统计学意义(P0.05),与模型组相比中药组具有统计学差异(P0.05)。结论:糖胰生2号方能显著改善临床糖耐量减低患者的症状,降低血糖血脂,改善胰岛素抵抗,并提高糖尿病大鼠血清胰岛素以及胰高血糖素样肽1的水平,保护糖尿病大鼠胰岛β细胞的功能,刺激胰岛β细胞的增殖和分化,抑制胰岛β细胞的凋亡。
[Abstract]:Objective: to investigate the effect of Tang-Yisheng No. 2 recipe on patients with impaired glucose tolerance and on serum insulin and glucagon like peptide-1 in diabetic rats. Method 1: 1. Clinical study: 60 patients with impaired glucose tolerance were randomly divided into treatment group and control group with 30 cases in each group. Control group: reasonable diet and exercise. Observe the changes of symptoms, blood glucose, blood lipid, body mass index, insulin resistance index before and after treatment. Experimental study: the diabetic rat model was established by using the method of double modeling (high sugar and high fat diet with appropriate amount of STZ). After 6 weeks of drug intervention, the diabetic rat model was established. The levels of serum insulin and glucagon-like peptide 1 were measured by enzyme-linked immunosorbent assay (Elisa). Results: the symptoms and signs of traditional Chinese medicine in the treatment group were improved (P0.05), compared with the control group (P0.01), the levels of 2h PG and HbA1cTCU TGN LDL-C in the treatment group were significantly lower than those in the control group (P0.05), but there was no significant difference between the treatment group and the control group (P0.05). Compared with the control group, the treatment group significantly decreased BMI (P0.05). Results: compared with the model group, the traditional Chinese medicine group and metformin and ciglutin groups could reduce body weight and fasting blood glucose (P0.05), the high dose group had significant advantage (P0.01), the ciglutin group and the traditional Chinese medicine group were compared with the model group. It has obvious advantage in increasing fasting insulin (P0.01), and the Chinese medicine group is more effective than metformin group and siglitatin group (P0.05), compared with the model group, metformin group, The insulin resistance index of ciglutin group and traditional Chinese medicine group decreased significantly (P0.01), but there was no significant difference between Chinese medicine group and metformin group and siglitatin group (P0.05), and the serum GLP-1 level of metformin group and siglitatin group was higher than that of model group. But there was no statistical significance (P0.05), compared with the model group, the traditional Chinese medicine group had statistical difference (P0.05). Conclusion: Tang Yisheng 2 prescription can significantly improve the symptoms of patients with impaired glucose tolerance, reduce blood glucose, blood lipid, improve insulin resistance, and increase the levels of serum insulin and glucagon like peptide 1 in diabetic rats. To protect the function of islet 尾 cells, stimulate the proliferation and differentiation of islet 尾 cells and inhibit the apoptosis of islet 尾 cells in diabetic rats.
【学位授予单位】：山东中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259

【引证文献】